Flavin-containing monooxygenase 3 and human disease

Expert Opinion on Drug Metabolism and Toxicology

Volumn 3, Issue 6, 2007, Pages 831-845

  Motika, Meike S ^a   Zhang, Jun ^a   Cashman, John R ^a  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

Author keywords

Diabetes mellitus; Human FMO3; Hypertension; Metabolism; Polymorphism; Trimethylaminuria

Indexed keywords

AMPHETAMINE; ANTIBIOTIC AGENT; ANTIHYPERTENSIVE AGENT; BENZYDAMINE; CHARCOAL; CIMETIDINE; CISAPRIDE; CYTOCHROME P450 3A4; DIMETHYLANILINE MONOOXYGENASE; FOLIC ACID; INSULIN; ITOPRIDE; METHAMPHETAMINE; RANITIDINE; RIBOFLAVIN; SULINDAC; TAMOXIFEN; THIAMAZOLE; TRIMETHYLAMINE;

ADENOMATOUS POLYP; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ATTENTION DEFICIT DISORDER; BREAST CANCER; DISEASE ASSOCIATION; DRUG METABOLISM; ENZYME ACTIVITY; GASTROESOPHAGEAL REFLUX; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEMOCHROMATOSIS; HUMAN; HYPERTENSION; METABOLIC DISORDER; NARCOLEPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PEPTIC ULCER; PROTEIN FUNCTION; QT PROLONGATION; REVIEW; TRIMETHYLAMINURIA;

ANIMALS; DRUG THERAPY; GENETIC DISEASES, INBORN; HUMANS; METABOLIC DETOXICATION, DRUG; MUTATION; OXYGENASES; POLYMORPHISM, GENETIC;

EID: 37349067414     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.3.6.831     Document Type: Review

References (83)

1. KRUEGER SK, WILLIAMS DE: Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol. Ther. (2005) 106(3):357-387.
2. CASHMAN JR: Structural and catalytic properties of the mammalian flavin-containing monooxygenase. Chem. Res. Toxicol. (1995) 8(2):166-181.
3. HINES RN, HOPP KA, FRANCO J, SAEIAN K, BEGUN FP: Alternative processing of the human FMO6 gene renders transcripts incapable of encoding a functional flavin-containing monooxygenase. Mol. Pharmacol. (2002) 62(2):320-325.
4. HERNANDEZ D, JANMOHAMED A, CHANDAN P, PHILLIPS IR, SHEPHARD EA: Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics (2004) 14(2):117-130.
5. FURNES B, FENG J, SOMMER SS, SCHLENK D: Identification of novel variants of the flavin-containing monooxygenase gene family in African Americans. Drug Metab. Dispos. (2003) 31(2):187-193.
6. CASHMAN JR, CAMP K, FAKHARZADEH SS et al.: Biochemical and clinical aspects of the human flavin-containing monooxygenase form 3 (FMO3) related to trimethylaminuria. Curr. Drug Metab. (2003) 4(2):151-170.
7. CRUZ-CORREA M, GIARDIELLO FM: Familial adenomatous polyposis. Gastrointest. Endosc. (2003) 58(6):885-894.
8. KELLER JJ, GIARDIELLO FM: Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol. Ther. (2003) 2(4 Suppl. 1):S140-S149.
9. HISAMUDDIN IM, WEHBI MA, CHAO A et al.: Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin. Cancer Res. (2004) 10(24):8357-8362.
10. CASHMAN JR, ZHANG J, LEUSHNER J, BRAUN A: Population distribution of human flavin-containmg monooxygenase form 3: gene polymorphisms. Drug Metab. Dispos. (2001) 29(12):1629-1637.
11. HISAMUDDIN IM, WEHBI MA, SCHMOTZER B et al.: Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol. Biomark. Prev. (2005) 14(10):2366-2369.
12. SHIMIZU M, YANO H, NAGASHIMA S et al.: Effect of genetic variants of the human flavin-containing monooxygenase 3 on N- and S-oxygenation activities. Drug Metab. Dispos. (2007) 35 (3):328-330.
13. KRUEGER SK, VANDYKE JE, WILLIAMS DE, HINES RN: The role of flavin-containing monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines. Drug Metab. Rev. (2006) 38(1-2):139-147.
14. SHIBUTANI S, SUZUKI N, LAXMI YR et al.: Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res. (2003) 63(15):4402-4406.
15. PHILLIPS DH: Understanding the genotoxicity of tamoxifen? Carcinogenesis (2001) 22(6):839-849.
16. KIM SY, SUZUKI N, LAXMI YR et al.: Formation of tamoxifen-DNA adducts in human endometrial explants exposed to α-hydroxytamoxifen. Chem. Res. Toxicol. (2005) 18(5):889-895.
17. CHUNG WG, PARK CS, ROH HK, LEE WK, CHA YN: Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J. Pharmacol. (2000) 84(2):213-220.
18. KANG JH, CHUNG WG, LEE KH et al.: Phenotypes of flavin-containing monooxygenase activity determined by ranitidine N-oxidation are positively correlated with genotypes of linked FMO3 gene mutations in a Korean population. Pharmacogenetics (2000) 10(1):67-78.
19. MAYATEPEK E, FLOCK B, ZSCHOCKE J: Benzydamine metabolism in vivo is impaired in patients with deficiency of flavin-containing monooxygenase 3. Pharmacogenetics (2004) 14(11):775-777.
20. CASHMAN JR, XIONG YN, XU L, JANOWSKY A: N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (form 3): role in bioactivation and detoxication. J. Pharmacol. Exp. Ther. (1999) 288(3):1251-1260.
21. BEDFORD TA, ROWBOTHAM DJ: Cisapride. Drug interactions of clinical significance. Drug Saf. (1996) 15(3):167-175.
22. MUSHIRODA T, DOUYA R, TAKAHARA E, NAGATA O: The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. Drug Metab. Dispos. (2000) 28(10):1231-1237.
23. MITCHELL SC, SMITH RL: Trimethylaminuria: the fish malodor syndrome. Drug Metab. Dispos. (2001) 29(4 Part 2):517-521.
24. SHIMIZU M, CASHMAN JR, YAMAZAKI H: Transient trimethylaminuria related to menstruation. BMC Med. Genet. (2007) 8:2.
25. LAMBERT DM, MAMER OA, AKERMAN BR et al.: In vivo variability of TMA oxidation is partially mediated by polymorphisms of the FMO3 gene. Mol. Genet. Metab. (2001) 73(3):224-229.
26. AKERMAN BR, LEMASS H, CHOW LM et al.: Trimethylaminuria is caused by mutations of the FMO3 gene in a North American cohort. Mol. Genet. Metab. (1999) 68(1):24-31.
27. MITCHELL SC, ZHANG AQ, BARRETT T, AYESH R, SMITH RL: Studies on the discontinuous N-oxidation of trimethylamine among Jordanian, Ecuadorian and New Guinean populations. Pharmacogenetics (1997) 7(1):45-50.
28. AYESH R, MITCHELL SC, ZHANG A, SMITH RL: The fish odour syndrome: biochemical, familial, and clinical aspects. BMJ (1993) 307(6905):655-657.
29. CHALMERS RA, BAIN MD, MICHELAKAKIS H, ZSCHOCKE J, ILES RA: Diagnosis and management of trimethylaminuria (FMO3 deficiency) in children. J. Inherit. Metab. Dis. (2006) 29(1):162-172.
30. MCCONNELL HW, MITCHELL SC, SMITH RL, BREWSTER M: Trimethylaminuria associated with seizures and behavioural disturbance: a case report. Seizure (1997) 6(4):317-321.
31. FRASER-ANDREWS EA, MANNING NJ, ASHTON GH et al.: Fish odour syndrome with features of both primary and secondary trimerhylaminuria. Clin. Exp. Dermatol. (2003) 28(2):203-205.
32. MITCHELL SC: Trimethylaminuria: susceptibility of heterozygotes. Lancet (1999) 354(9196):2164-2165.
33. ZSCHOCKE J, KOHLMUELLER RD, QUAK E et al.: Mild trimethylaminuria caused by common variants in FMO3 gene. Lancet (1999) 354(9181):834-835.
34. CASHMAN JR, ZHANG J: Interindividual differences of human flavin-containing monooxygenase 3: genetic polymorphisms and functional variation. Drug Metab. Dispos. (2002) 30(10):1043-1052.
35. ZHANG AQ, MITCHELL SC, SMITH RL: Exacerbation of symptoms of fish-odour syndrome during menstruation. Lancet (1996) 348(9043):1740-1741.
36. YAMAZAKI H, FUJIEDA M, TOGASHI M et al.: Effects of the dietary supplements, activated charcoal and copper chlorophyllin, on urinary excretion of nimethylamine in Japanese trimethylaminuria patients. Life Sci. (2004) 74(22):2739-2747.
37. CASHMAN JR, XIONG Y, LIN J et al.: In vitro and in vivo inhibition of human flavin-containing monooxygenase form 3 (FMO3) in the presence of dietary indoles. Biochem. Pharmacol. (1999) 58(6):1047-1055.
38. ZHOU J, SHEPHARD EA: Mutation, polymorphism and perspectives for the future of human flavin-containing monooxygenase 3. Mutat. Res. (2006) 612(3):165-171.
39. MITCHELL SC: The fish-odor syndrome. Perspect. Biol. Med. (1996) 39(4):514-526.
40. ZHANG AQ, MITCHELL SC, SMITH RL: Dietary precursors of trimethylamine in man: a pilot study. Food Chem. Toxicol. (1999) 37(5):515-520.
41. TREACY EP, AKERMAN BR, CHOW LM et al.: Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum. Mol. Genet. (1998) 7(5):839-845.
42. CASHMAN JR: Human flavin-containing monooxygenase (form 3): polymorphisms and variations in chemical metabolism. Pharmacogenomics (2002) 3(3):325-339.
43. ROUER E, ROUET P, DELPECH M, LEROUX JP: Purification and comparison of liver microsomal flavin-containing monooxygenase from normal and streptozotocin-diabetic rats. Biochem. Pharmacol. (1988) 37(18):3455-3459.
44. WANG T, SHANKAR K, RONIS MJ, MEHENDALE HM: Potentiation of thioacetamide liver injury in diabetic rats is due to induced CYP2E1. J. Pharmacol. Exp. Ther. (2000) 294(2):473-479.
45. BORBAS T, BENKO B, DALMADI B, SZABO I, TIHANYI K: Insulin in flavin-containing monooxygenase regulation. Flavin-containing moncoxygenase and cytochrome P450 activities in experimental diabetes. Eur. J. Pharm. Sci. (2006) 28(1-2):51-58.
46. FALLS JG, RYU DY, CAO Y, LEVI PE, HODGSON E: Regulation of mouse liver flavin-containing monooxygenases 1 and 3 by sex steroids. Arch. Biochem. Biophys. (1997) 342(2):212-223.
47. TAKAMURA T, SAKURAI M, OTA T et al.: Genes for systemic vascular complications are differentially expressed in the livers of type 2 diabetic patients. Diabetologia (2004) 47(4):638-647.
48. BARBER M, CONRAD ME, UMBREIT JN, BARTON JC, MOORE EG: Abnormalities of flavin monooxygenase as an etiology for sideroblastic anemia. Am. J. Hematol. (2000) 65(2):149-153.
49. MUCKENTHALER M, ROY CN, CUSTODIO AO et al.: Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat. Genet. (2003) 34(1):102-107.
50. CASHMAN JR, ZHANG J: Human flavin-containing monooxygenases. Annu. Rev. Pharmacol. Toxicol. (2006) 46:65-100.
51. DOLAN C, SHIELDS DC, STANTON A et al.: Polymorphisms of the flavin containing monooxygenase 3 (FMO3) gene do not predispose to essential hypertension in Caucasians. BMC Med Genet. (2005) 6:41.
52. LARSEN BK, SCHLENK D: Effect of salinity on flavin-containing monooxygenase expression and activity in rainbow trout (Oncorhynchus mykiss). J. Comp. Physiol. [B] (2001) 171(5):421-429.
53. LIN J, CASHMAN JR: Detoxication of tyramine by the flavin-containing monooxygenase: stereoselective formation of the trans oxime. Chem. Res. Toxicol. (1997) 10(8):842-852.
54. CASHMAN JR, AKERMAN BR, FORREST SM, TREACY EP: Population-specific polymorphisms of the human FMO3 gene: significance for detoxication. Drug Metab. Dispos. (2000) 28(2):169-173.
55. KOUKOURITAKI SB, POCH MT, CABACUNGAN ET, MCCARVER DG, HINES RN: Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upsteam haplotype variants. Mol. Pharmacol. (2005) 68(2):383-392.
56. ZHANG J, TRAN Q, LATTARD V, CASHMAN JR: Deleterious mutations in the flavin-containing monooxygenase 3 (FMO3) gene causing trimethylaminuria. Pharmacogenetics (2003) 13(8):495-500.
57. TERESA E, LONARDO F, FIUMARA A et al.: A spectrum of molecular variation in a cohort of Italian families with trimethylaminuria: identification of three novel mutations of the FMO3 gene. Mol. Genet. Metab. (2006) 88(2):192-195.
58. MAZON RAMOS A, GIL-SETAS A, BERRADE ZUBIRI S et al.: Primary trimethylaminuria or fish odor syndrome. A novel mutation in the first documented case in Spain. Med. Clin. (Barc.) (2003) 120(6):219-221.
59. DOLPHIN CT, JANMOHAMED A, SMITH RL, SHEPHARD EA, PHILLIPS IR: Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FMO3) gene in patients with fish-odour syndrome. Pharmacogenetics (2000) 10(9):799-807.
60. DOLPHIN CT, JANMOHAMED A, SMITH RL, SHEPHARD EA, PHILLIPS IR: Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat. Genet. (1997) 17(4):491-494.
61. YEUNG CK, ADMAN ET, RETTIE AE: Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria. Arch. Biochem. Biophys. (2007) 464(2):251-259.
62. BASARAB T, ASHTON GH, MENAGE HP, MCGRATH JA: Sequence variations in the flavin-containing mono-oxygenase 3 gene (FMO3) in fish odour syndrome. Br. J. Dermatol. (1999) 140(1):164-167.
63. KOUKOURITAKI SB, POCH MT, HENDERSON MC et al.: Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants. J. Pharmacol. Exp. Ther. (2007) 320(1):266-273.
64. KUBOTA M, NAKAMOTO Y, NAKAYAMA K et al.: A mutation in the flavin-containing monooxygenase 3 gene and its effects on catalytic activity for N-oxidation of trimethylamine in vitro. Drug Metab. Pharmacokinet. (2002) 17(3):207-213.
65. MURPHY HC, DOLPHIN CT, JANMOHAMED A et al.: A novel mutation in the flavin-containing monooxygenase 3 gene, FM03, that causes fish-odour syndrome: activity of the mutant enzyme assessed by proton NMR spectroscopy. Pharmacogenetics (2000) 10(5):439-451.
66. YAMAZAKI H, SHIMIZU M: Genetic polymorphism of the flavin-containing monooxygenase 3 (FMO3) associated with trimethylaminuria (Fish odor syndrome): observations from Japanese patients. Curr. Drug Metab. (2007) 8(5):487-491.
67. SHIMIZU M, TOMIOKA S, MURAYAMA N, YAMAZAKI H: Missense and nonsense mutations of the flavin-containing monooxygenase 3 gene in a Japanese cohort. Drug Metab. Pharmacokinet. (2007) 22(1):61-64.
68. FUJIEDA M, YAMAZAKI H, TOGASHI M, SAITO T, KAMATAKI T: Two novel single nucleotide polymorphisms (SNPs) of the FMO3 gene in Japanese. Drug Metab. Pharmacokinet. (2003) 18(5):333-335.
69. LATTARD V, ZHANG J, TRAN Q et al.: Two new polymorphisms of the FMO3 gene in Caucasian and African-American populations: comparative genetic and functional studies. Drug Metab. Dispos. (2003) 31(7):854-860.
70. LATTARD V, ZHANG J, CASHMAN JR: Alternative processing events in human FMO genes. Mol. Pharmacol. (2004) 65(6):1517-1525.
71. CASHMAN JR: The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov. Today (2004) 9(13):574-581.
72. CASHMAN JR, BI YA, LIN J et al.: Human flavin-containing monooxygenase form 3: cDNA expression of the enzymes containing amino acid substitutions observed in individuals with trimethylaminuria. Chem. Res. Toxicol. (1997) 10(8):837-841.
73. SACHSE C, RUSCHEN S, DETTLING M et al.: Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. Clin. Pharmacol. Ther. (1999) 66(4):431-438.
74. CASHMAN JR: Some distinctions between flavin-containing and cytochrome P450 monooxygenases. Biochem. Biophys. Res. Commun. (2005) 338(1):599-604.
75. PRETI G, UBRIANI R, KIM J et al.: Identification of a novel R223Q missense mutation in the flavin-containing monooxygenase 3 gene in trimethylaminuria. J. Invest. Dermatol. (2002) 119(1):207-350.
76. CASHMAN JR: Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr. Drug Metab. (2000) 1(2):181-191.
77. TUGNAIT M, HAWES EM, MCKAY G et al.: N-oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab. Dispos. (1997) 25(4):524-527.
78. VYAS PM, ROYCHOWDHURY S, KOUKOURITAKI SB et al.: Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes. II. Expression and role of flavin-containing monooxygenases and peroxidases. J. Pharmacol. Exp. Ther. (2006) 319(1):497-505.
79. KAJITA J, INANO K, FUSE E, KUWABARA T, KOBAYASHI H: Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. Drug Metab. Dispos. (2002) 30(12):1504-1511.
80. MOLINA AJ, MERINO G, PRIETO JG et al.: Absorption and metabolism of albendazole after intestinal ischemia/reperfusion. Eur. J. Pharm. Sci. (2007) 31(1):16-24.
81. CASHMAN JR, PARK SB, YANG ZC et al.: Chemical, enzymatic, and human enantioselective S-oxygenation of cimetidine. Drug Metab. Dispos. (1993) 21(4):587-597.
82. QIAN L, ORTIZ DE MONTELLANO PR: Oxidative activarion of thiacetazone by the Mycobarterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3. Chem. Res. Toxicol. (2006) 19(3):443-449.
83. ATTAR M, DONG D, LING KH, TANG-LIU DD: Cytochrome P450 2C8 and flavin-containing monooxygenases are involved in the metabolism of tazarotenic acid in humans. Drug Metab. Dispos. (2003) 31(4):476-481.